A recent study challenges the popular belief that omega-3 supplements can enhance brain health and cognitive function. Researchers at Keck Medicine of the University of Southern California conducted a two-year trial involving older adults at risk of Alzheimer’s disease. The study revealed that high doses of omega-3 did not show any significant improvement in memory, cognitive abilities, or prevention of brain cell loss in areas linked to the disease.
Lead investigator Dr. Hussein Naji Yassine emphasized that while omega-3s are essential for forming brain cell connections crucial for cognition, the study did not support the use of fish oil supplements as a preventative measure against Alzheimer’s. The research recruited 365 adults between 55 and 80 years old who seldom consumed fish, a natural source of omega-3 fatty acids, and had an elevated risk of Alzheimer’s.
Participants were randomly divided into groups receiving daily fish oil supplements or placebos. The supplement contained 2,000 mg of docosahexaenoic acid (DHA), a vital omega-3 fatty acid for brain function. Although DHA levels in the brain increased by 17% after six months, cognitive tests after two years showed no significant difference between those taking DHA and those on placebos. Brain scans also indicated no reduction in hippocampal shrinkage, a key area for memory and Alzheimer’s progression.
The researchers are now exploring why omega-3s can reach the brain without yielding observable benefits. They suggest that incorporating omega-3s into a Mediterranean-style diet, naturally abundant in these fatty acids, may be more effective in lowering Alzheimer’s risk.
Dr. Yassine highlighted ongoing efforts to develop medications that could enhance the brain’s utilization of omega-3s for preserving cognitive function. While lifestyle factors like exercise, sleep quality, and a balanced diet are crucial for brain health, the study underscores the importance of overall health in reducing Alzheimer’s risk.
The study also included researchers Lina D’Orazio, Lon Schneider, Michael Harrington, and Meredith Braskie from the University of Southern California’s Keck School of Medicine.
